Fig. 8: Inhibition of primary and brain-metastatic tumors. | Nature Communications

Fig. 8: Inhibition of primary and brain-metastatic tumors.

From: MMP-2-triggered, mitochondria-targeted PROTAC-PDT therapy of breast cancer and brain metastases inhibition

Fig. 8

a Bioluminescence imaging of mice bearing with brain-metastatic tumors. b Semi-quantification results of bioluminescence imaging on the 8th, 16th, and 24th post-tumor inoculation (n = 10 mice). c Tumor volume of primary tumors (n = 10 mice). d, e The ex vivo image and weights of primary tumors (n = 10 mice). The G1–G4 represent Control, CFMPD + L, BET6@CFPD + L, and BET6@CFMPD + L, respectively. f Percent survival analyses of mice bearing with brain-metastatic and primary tumors (n = 10 mice). And survival study was analyzed through Two-sided log-rank (Mantel–Cox) test. g H&E staining of brain tissues (scale bar = 2 mm). All data are presented as mean ± SD. Two-tailed Student’s t test and One-way analysis of variance (ANOVA) with a Tukey post hoc test were used for the statistical comparison between the two groups and among multiple groups, respectively. A significant difference was considered when the p value was < 0.05. Source data are provided as a Source Data file.

Back to article page